CarlosEduardoMillaMD
Pediatric Pulmonology • Palo Alto, CAAssociate Professor, Pediatrics - Pulmonary Medicine, Stanford University Medical Center
Dr. Milla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
725 Welch Rd
Palo Alto, CA 94304Phone+1 650-497-8000Fax+1 650-723-5201
Education & Training
Cayetano Heredia UniversityClass of 1986, MD
Certifications & Licensure
CA State Medical License 2007 - 2026
MN State Medical License 1992 - 2007- American Board of Pediatrics Pediatric Pulmonology
Clinical Trials
- A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele Start of enrollment: 2019 Nov 25
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 10 citationsCFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTRMolly B. Sheridan, Timothy Hefferon, Nulang Wang, Christian A. Merlo, Carlos Milla
Journal of Medical Genetics. 2011-04-01 - 51 citationsMacrophage-derived IL-6 trans-signaling as a novel target in the pathogenesis of bronchopulmonary dysplasia.Dharmesh Hirani, Cristina M. Alvira, Soula Danopoulos, Carlos Milla, Michele Donato
The European Respiratory Journal. 2021-08-26 - 176 citationsIvacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm studyMargaret Rosenfeld, Claire E. Wainwright, Mark Higgins, Linda T Wang, Charlotte M. McKee
The Lancet. Respiratory Medicine. 2018-07-01
Press Mentions
- Double CF Combination Safe, Effective in 1- to 2-Year-OldsDecember 30th, 2022
- Scientists Decipher the Danger of Gummy Phlegm in Severe COVID-19June 24th, 2022
- Stanford Scientists Decipher the Danger of Gummy Phlegm in Severe COVID-19June 22nd, 2022
- Join now to see all
Grant Support
- Inhaled Sodium Pyruvate For The Treatment Of Cystic Fibrosis A Phase I, DoubleNational Center For Research Resources2007
- A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study Of Denufosol TetrasNational Center For Research Resources2007
- A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial WithNational Center For Research Resources2006–2007
- Assessment Of Induced Sputum As A Tool To Evaluate Anti-Inflammatory Agents In CNational Center For Research Resources2006
- A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study Of DNational Center For Research Resources2006
- Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Of Aerosolized TGNational Center For Research Resources2004–2006
- A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study Of InNational Center For Research Resources2005
- Safety And Tolerability Study Of Aztreonam For Inhalation In Cystic FibrosisNational Center For Research Resources2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
